Literature DB >> 30168753

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Ganesh Raghu, Martine Remy-Jardin, Jeffrey L Myers, Luca Richeldi, Christopher J Ryerson, David J Lederer, Juergen Behr, Vincent Cottin, Sonye K Danoff, Ferran Morell, Kevin R Flaherty, Athol Wells, Fernando J Martinez, Arata Azuma, Thomas J Bice, Demosthenes Bouros, Kevin K Brown, Harold R Collard, Abhijit Duggal, Liam Galvin, Yoshikazu Inoue, R Gisli Jenkins, Takeshi Johkoh, Ella A Kazerooni, Masanori Kitaichi, Shandra L Knight, George Mansour, Andrew G Nicholson, Sudhakar N J Pipavath, Ivette Buendía-Roldán, Moisés Selman, William D Travis, Simon Walsh, Kevin C Wilson.   

Abstract

BACKGROUND: This document provides clinical recommendations for the diagnosis of idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society.
METHODS: The evidence syntheses were discussed and recommendations formulated by a multidisciplinary committee of IPF experts. The evidence was appraised and recommendations were formulated, written, and graded using the Grading of Recommendations, Assessment, Development, and Evaluation approach.
RESULTS: The guideline panel updated the diagnostic criteria for IPF. Previously defined patterns of usual interstitial pneumonia (UIP) were refined to patterns of UIP, probable UIP, indeterminate, and alternate diagnosis. For patients with newly detected interstitial lung disease (ILD) who have a high-resolution computed tomography scan pattern of probable UIP, indeterminate, or an alternative diagnosis, conditional recommendations were made for performing BAL and surgical lung biopsy; because of lack of evidence, no recommendation was made for or against performing transbronchial lung biopsy or lung cryobiopsy. In contrast, for patients with newly detected ILD who have a high-resolution computed tomography scan pattern of UIP, strong recommendations were made against performing surgical lung biopsy, transbronchial lung biopsy, and lung cryobiopsy, and a conditional recommendation was made against performing BAL. Additional recommendations included a conditional recommendation for multidisciplinary discussion and a strong recommendation against measurement of serum biomarkers for the sole purpose of distinguishing IPF from other ILDs.
CONCLUSIONS: The guideline panel provided recommendations related to the diagnosis of IPF.

Entities:  

Keywords:  idiopathic pulmonary fibrosis; interstitial lung disease; pulmonary fibrosis

Mesh:

Year:  2018        PMID: 30168753     DOI: 10.1164/rccm.201807-1255ST

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  759 in total

Review 1.  Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?

Authors:  Christopher L Mosher; Robert J Mentz
Journal:  Am Heart J       Date:  2020-05-06       Impact factor: 4.749

2.  Pharmacological treatment of acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study of 88 patients.

Authors:  Susumu Sakamoto; Hiroshige Shimizu; Takuma Isshiki; Atsuko Kurosaki; Sakae Homma
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

3.  Survey of Physician's Knowledge, Attitudes, and Practices Regarding Idiopathic Pulmonary Fibrosis in Turkey.

Authors:  Haluk Türktaş; Gülfer Okumuş; Oğuz Uzun; Özlem Özdemir Kumbasar; Göksel Altınışık; Züleyha Bingöl; Şermin Börekçi; Vincent Cottin; Benan Müsellim
Journal:  Turk Thorac J       Date:  2020-01-01

4.  Chronic Hypersensitivity Pneumonitis, an Interstitial Lung Disease with Distinct Molecular Signatures.

Authors:  Haruhiko Furusawa; Jonathan H Cardwell; Tsukasa Okamoto; Avram D Walts; Iain R Konigsberg; Jonathan S Kurche; Tami J Bang; Marvin I Schwarz; Kevin K Brown; Jonathan A Kropski; Mauricio Rojas; Carlyne D Cool; Joyce S Lee; Paul J Wolters; Ivana V Yang; David A Schwartz
Journal:  Am J Respir Crit Care Med       Date:  2020-11-15       Impact factor: 21.405

5.  Pulmonary Fibrosis: A Guide for the Perplexed.

Authors:  Charles S White; Jeffrey R Galvin
Journal:  Radiol Cardiothorac Imaging       Date:  2021-02-25

6.  Registration of the extracellular matrix components constituting the fibroblastic focus in idiopathic pulmonary fibrosis.

Authors:  Jeremy Herrera; Colleen Forster; Thomas Pengo; Angeles Montero; Joe Swift; Martin A Schwartz; Craig A Henke; Peter B Bitterman
Journal:  JCI Insight       Date:  2019-01-10

7.  Revealing the Secrets of Idiopathic Pulmonary Fibrosis.

Authors:  Richard K Albert; David A Schwartz
Journal:  N Engl J Med       Date:  2019-01-03       Impact factor: 91.245

8.  Small airways pathology in idiopathic pulmonary fibrosis: a retrospective cohort study.

Authors:  Stijn E Verleden; Naoya Tanabe; John E McDonough; Dragoş M Vasilescu; Feng Xu; Wim A Wuyts; Davide Piloni; Laurens De Sadeleer; Stijn Willems; Cindy Mai; Jeroen Hostens; Joel D Cooper; Erik K Verbeken; Johny Verschakelen; Craig J Galban; Dirk E Van Raemdonck; Thomas V Colby; Marc Decramer; Geert M Verleden; Naftali Kaminski; Tillie-Louise Hackett; Bart M Vanaudenaerde; James C Hogg
Journal:  Lancet Respir Med       Date:  2020-02-13       Impact factor: 30.700

9.  Reply.

Authors:  Erin M Wilfong; Kevin W Bayram; Leslie J Crofford
Journal:  Arthritis Rheumatol       Date:  2019-03-02       Impact factor: 10.995

10.  Epidemiology of idiopathic pulmonary fibrosis: a population-based study in primary care.

Authors:  Sergio Harari; Michele Davì; Alice Biffi; Antonella Caminati; Alessandra Ghirardini; Valeria Lovato; Claudio Cricelli; Francesco Lapi
Journal:  Intern Emerg Med       Date:  2019-09-20       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.